Search Result
Results for "
antidiabetic agent
" in MedChemExpress (MCE) Product Catalog:
4
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-109144
-
DWP-16001
|
SGLT
|
Metabolic Disease
|
Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor .
|
-
-
- HY-B2099A
-
1-Butylbiguanide hydrochloride
|
AMPK
|
Cancer
|
Buformin hydrochloride (1-Butylbiguanide hydrochloride), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin hydrochloride decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin hydrochloride also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al) .
|
-
-
- HY-161429
-
|
Amylases
Glucosidase
|
Metabolic Disease
|
Antidiabetic agent 5 (compound S1) is a antidiabetic agent. Antidiabetic agent 5 inhibits the activity of α-glucosidase and α-amylase with IC50 values of 3.91, 8.89 µM, respectively. Antidiabetic agent 5 decreases sugar levels. Antidiabetic agent 5 has the potential for the research of type-II diabetes .
|
-
-
- HY-155961
-
-
-
- HY-B2099
-
1-Butylbiguanide
|
AMPK
|
Metabolic Disease
Cancer
|
Buformin (1-Butylbiguanide), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al) .
|
-
-
- HY-121731
-
-
-
- HY-101758
-
-
-
- HY-120401
-
Desaglybuzole
|
Others
|
Metabolic Disease
|
Glybuzole (Desaglybuzole) is an orally active hypoglycaemic agent that has antidiabetic effect .
|
-
-
- HY-16397A
-
Phenethylbiguanide hydrochloride
|
AMPK
Autophagy
|
Cancer
|
Phenformin hydrochloride is an anti-diabetic agent from the biguanide class, can activate AMPK activity.
|
-
-
- HY-P0058
-
-
-
- HY-P0058B
-
-
-
- HY-15516
-
Sotagliflozin
Maximum Cited Publications
10 Publications Verification
LX-4211; LP-802034
|
SGLT
|
Metabolic Disease
|
Sotagliflozin (LX-4211) is a potent dual SGLT2/1 inhibitor. Antidiabetic agents.
|
-
-
- HY-17451
-
-
-
- HY-P0058A
-
-
-
- HY-W041324
-
|
Others
|
Infection
|
Glimepiride sulfonamide is a intermediate, and can be used to synthesize Glimepiride (HY-B0104) (antidiabetic agent) .
|
-
-
- HY-B1114
-
AR-DF 26
|
Others
|
Metabolic Disease
|
Gliquidone (AR-DF 26) is an anti-diabetic agent in the sulfonylurea class, used in the treatment of diabetes mellitus type 2.
|
-
-
- HY-W010649
-
|
Antibiotic
|
Others
|
Isoxazole is a agent scaffold that can be used to develop new agents with various biological activities (e.g. anti-microbial, anti-viral, anti-cancer, anti-inflammatory, immunomodulatory, anti-convulsant or anti-diabetic properties) .
|
-
-
- HY-16397AS
-
Phenethylbiguanide-d5 hydrochloride
|
Isotope-Labeled Compounds
AMPK
Autophagy
|
Cancer
|
Phenformin-d5 (hydrochloride) is the deuterium labeled Phenformin hydrochloride. Phenformin hydrochloride is an anti-diabetic agent from the biguanide class, can activate AMPK activity[1][2].
|
-
-
- HY-131504A
-
|
Glucosidase
|
Metabolic Disease
|
Valienamine is the alpha-glucosidase inhibitor. Valienamine is the key functional component of many natural glycosidase inhibitors including the crop protectant validamycin A and the antidiabetic agent acarbose .
|
-
-
- HY-B1114S
-
AR-DF 26-d6
|
Isotope-Labeled Compounds
|
Metabolic Disease
|
Gliquidone-d6 is deuterium labeled Gliquidone. Gliquidone (AR-DF 26) is an anti-diabetic agent in the sulfonylurea class, used in the treatment of diabetes mellitus type 2.
|
-
-
- HY-115978
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-2 (compound 5d) is a potent α-Glucosidase inhibitor with an IC50 of 9.48 µM. α-Glucosidase-IN-2 is an antidiabetic agent .
|
-
-
- HY-B1114R
-
|
Others
|
Metabolic Disease
|
Gliquidone (Standard) is the analytical standard of Gliquidone. This product is intended for research and analytical applications. Gliquidone (AR-DF 26) is an anti-diabetic agent in the sulfonylurea class, used in the treatment of diabetes mellitus type 2.
|
-
-
- HY-N7912
-
(2S)-Pterosin A
|
Others
|
Metabolic Disease
|
Pterosin A is an orally active anti-diabetic agent. Pterosin A promotes glucose uptake, increases serum insulin, and improves hyperglycemia and glucose intolerance in diabetic mice. Pterosin A can be isolated from Pteridium aquilinum .
|
-
-
- HY-115940
-
|
Aldose Reductase
|
Metabolic Disease
|
Aldose reductase-IN-2 (Compound 5f) is a potent inhibitor of aldose reductase (AR). Aldose reductase-IN-2 has antioxidation capacity. Aldose reductase-IN-2 is a promising anti-diabetic complications agent .
|
-
-
- HY-B0401A
-
|
Apoptosis
|
Metabolic Disease
|
Tolbutamide sodium is a potent and orally active antidiabetic agent. Tolbutamide sodium induces apoptosis in a Ca 2+ dependent manner in pancreatic β-cells. Tolbutamide sodium has the potential for the research of non-insulin-dependent diabetes mellitus .
|
-
-
- HY-N2486
-
|
Fatty Acid Synthase (FASN)
Apoptosis
|
Cancer
|
Desoxyrhaponticin is a kind of oral drug that inhibits effective fatty acid synthesis (FASN), and has a fatal effect on cancer cells. Desoxyrhaponticin has the ability to inhibit glucose uptake, improve oral glucose tolerance as a diabetic agent, and possess anti-diabetic effects.
|
-
-
- HY-125012
-
|
MAP4K
|
Metabolic Disease
|
MAP4K4-IN-3 (Compound 17) is a potent and selective MAP4K4 inhibitor with an IC50 of 14.9 nM in kinase assay, an IC50 of 470 nM in cell assay. Antidiabetic agent .
|
-
-
- HY-N2413
-
|
Others
|
Metabolic Disease
|
Gomisin D, a lignan compound isolated from Fructus Schisandra, is a potential antidiabetic and anti-Alzheimer’s agent. Gomisin D inhibits UDP-Glucuronosyltransferases activity and scavenges ABTS(+) radicals. Gomisin D is used as a quality marker of Shengmai San and shenqi Jiangtang Granule .
|
-
-
- HY-B0254
-
CP 28720; K 4024
|
Potassium Channel
|
Metabolic Disease
|
Glipizide (CP 2872; K 4024) a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2 diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium (KATP) channels among β cells of pancreatic islets of Langerhans .
|
-
-
- HY-14894
-
ASP1941
|
SGLT
|
Metabolic Disease
|
Ipragliflozin (ASP1941) is an orally active and selective SGLT2 inhibitor with IC50s of 7.38 and 1876 nM, 6.73 and 1166 nM, 5.64 and 1380 nM for human SGLT2 and SGLT1, rat SGLT2 and SGLT1, mouse SGLT2 and SGLT1, respectively. Antidiabetic agent .
|
-
-
- HY-152158
-
|
Glucosidase
|
Metabolic Disease
|
α-Glucosidase-IN-22 (compound 7i), a benzimidazole, is a potent α-glucosidase inhibitor with an IC50 of 0.64 μM. α-Glucosidase-IN-22 is a potent anti-diabetic agent and has the potential for type 2 diabetes mellitus (T2DM) research .
|
-
-
- HY-16397
-
Phenethylbiguanide
|
Mitochondrial Metabolism
AMPK
Apoptosis
|
Metabolic Disease
Cancer
|
Phenformin (1-phenethylbiguanide) is an orally active antidiabetic and anticancer agent. Phenformin has an incidence of associated lactic acidosis. Phenformin acts through acting AMPK activation and blocking mTOR pathway. Phenformin is also a substrate of P-glycoprotein (P-gp), and an OXPHOS inhibitor. Phenformin induces cancer cell apoptosis .
|
-
-
- HY-N11844
-
|
Amylases
|
Metabolic Disease
|
Quercetin 3-(6″-caffeoylsophoroside) is an orally active α-amylase inhibitor, with an IC50 of 73.66 μg/mL. Quercetin 3-(6″-caffeoylsophoroside) presents in thehydro-methanolic extract of Cardamine hirsuta Linn. Quercetin 3-(6″-caffeoylsophoroside) shows the antidiabetic activities by oxidative stress reduction and α-amylase inhibition. Quercetin 3-(6″-caffeoylsophoroside) can be used for diabetes mellitus research .
|
-
-
- HY-14621
-
Vanillylacetone; Gingerone
|
NF-κB
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
Zingerone (Vanillylacetone) is a nontoxic methoxyphenol isolated from Zingiber officinale, with potent anti-inflammatory, antidiabetic, antilipolytic, antidiarrhoeic, antispasmodic and anti-tumor properties . Zingerone alleviates oxidative stress and inflammation, down-regulates NF-κB mediated signaling pathways . Zingerone acts as an anti-mitotic agent, and inhibits the growth of neuroblastoma cells .
|
-
-
- HY-134769
-
-
-
- HY-N12353
-
|
Phosphatase
|
Metabolic Disease
|
Stevisalioside A (Compound 2) can be isolated from Stevia serrata roots. Stevisalioside A is an orally active antidiabetic agent. Stevisaliosides A inhibits PTP1B (IC50: 526.8 μM). Stevisalioside A reduces blood glucose levels and the postprandial peak in oral glucose and insulin tolerance tests in Streptozotocin (HY-13753) induced hyperglycemic mice .
|
-
-
- HY-42680
-
D-(-)-Tagatose
|
Endogenous Metabolite
|
Metabolic Disease
Cancer
|
D-Tagatose (D-(-)-Tagatose) is a rare monosaccharide found in nature with prebiotic characteristics. D-Tagatose is as a substitute for sucrose and a low-calorie sweetener in foodstuffs such as gum, fruit juice, and beverages. D-Tagatose is also a potential antidiabetic agent for the research of type II diabetes and a prebiotic to help elevate beneficial bacteria in the colon, prevent colon cancer, and lower cholesterol .
|
-
-
- HY-N6883
-
|
Aldose Reductase
|
Metabolic Disease
|
6-Methoxytricin (Compound 6) is an flavonoid isolated from Artemisia iwayomogi. 6-Methoxytricin (Compound 6) is an inhibitor on aldose reductase (AR) and advanced glycation endproduct (AGE) formation activities with IC50 values of 30.29 μM and 134.88 μM, respectively. 6-Methoxytricin (Compound 6) has potential as an anti-diabetic complications agent .
|
-
-
- HY-17638
-
DSP-3235 free base; KGA-3235 free base; GSK-1614235 free base
|
SGLT
|
Metabolic Disease
|
Mizagliflozin (DSP-3235 free base) is a potent, orally active and selective SGLT1 inhibitor, with a Ki of 27 nM for human SGLT1. Mizagliflozin displays 303-fold selectivity over SGLT2. Mizagliflozin is used as an antidiabetic agent that can modify postprandial blood glucose excursion. Mizagliflozin also exhibits potential in the amelioration of chronic constipation .
|
-
-
- HY-B2099S
-
1-Butylbiguanide-d9 hydrochloride
|
Isotope-Labeled Compounds
AMPK
|
Metabolic Disease
Cancer
|
Buformin-d9 (hydrochloride) is the deuterium labeled Buformin. Buformin (1-Butylbiguanide), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al)[1].
|
-
-
- HY-B0254S
-
|
Potassium Channel
|
Metabolic Disease
|
Glipizide-d11 is the deuterium labeled Glipizide. Glipizide (CP 2872; K 4024) a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2 diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium (KATP) channels among β cells of pancreatic islets of Langerhans[1][2].
|
-
-
- HY-N4103
-
|
PARP
Endogenous Metabolite
|
Metabolic Disease
Cancer
|
Fucosterol is a sterol isolated from algae, seaweed or diatoms.?Fucosterol exhibits various biological activities, including antioxidant, anti-adipogenic, blood cholesterol reducing, anti-diabetic and anti-cancer activities . Fucosterol regulates adipogenesis via inhibition of?PPARα?and?C/EBPα?expression and can be used for anti-obesity agents development research .
|
-
-
- HY-14894R
-
|
SGLT
|
Metabolic Disease
|
Ipragliflozin (Standard) is the analytical standard of Ipragliflozin. This product is intended for research and analytical applications. Ipragliflozin (ASP1941) is an orally active and selective SGLT2 inhibitor with IC50s of 7.38 and 1876 nM, 6.73 and 1166 nM, 5.64 and 1380 nM for human SGLT2 and SGLT1, rat SGLT2 and SGLT1, mouse SGLT2 and SGLT1, respectively. Antidiabetic agent .
|
-
-
- HY-B0254R
-
|
Potassium Channel
|
Metabolic Disease
|
Glipizide (Standard) is the analytical standard of Glipizide. This product is intended for research and analytical applications. Glipizide (CP 2872; K 4024) a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2 diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium (KATP) channels among β cells of pancreatic islets of Langerhans .
|
-
-
- HY-117167
-
|
Thyroid Hormone Receptor
|
Cancer
|
KB-141 is a potent and selective TRβ agonist. The IC50 values are 23.9 nM and 3.3 nM for binding affinities from displacement of T3 from hTRα1 and hTRβ1, respectively. KB-141 has anti-obesity, anti-diabetic, and lipid-lowering effects?and can be used as an anti-cholesteremic agent in vivo .
|
-
-
- HY-148922
-
|
PPAR
|
Metabolic Disease
|
PPARα/γ agonist 2 is an orally active PPARα full agonist and PPARγ partial agonist. PPARα/γ agonist 2 activates PPARα and PPARγ with EC50 values of 0.95 μM and 0.91 μM respectively. PPARα/γ agonist 2 is also a PTP1B inhibitor. PPARα/γ agonist 2 is an anti-diabetic agent .
|
-
-
- HY-N4103R
-
|
PARP
Endogenous Metabolite
|
Metabolic Disease
Cancer
|
Fucosterol (Standard) is the analytical standard of Fucosterol. This product is intended for research and analytical applications. Fucosterol is a sterol isolated from algae, seaweed or diatoms.?Fucosterol exhibits various biological activities, including antioxidant, anti-adipogenic, blood cholesterol reducing, anti-diabetic and anti-cancer activities . Fucosterol regulates adipogenesis via inhibition of?PPARα?and?C/EBPα?expression and can be used for anti-obesity agents development research .
|
-
Cat. No. |
Product Name |
Target |
Research Area |
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0254S
-
|
Glipizide-d11 is the deuterium labeled Glipizide. Glipizide (CP 2872; K 4024) a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2 diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium (KATP) channels among β cells of pancreatic islets of Langerhans[1][2].
|
-
-
- HY-16397AS
-
|
Phenformin-d5 (hydrochloride) is the deuterium labeled Phenformin hydrochloride. Phenformin hydrochloride is an anti-diabetic agent from the biguanide class, can activate AMPK activity[1][2].
|
-
-
- HY-B1114S
-
|
Gliquidone-d6 is deuterium labeled Gliquidone. Gliquidone (AR-DF 26) is an anti-diabetic agent in the sulfonylurea class, used in the treatment of diabetes mellitus type 2.
|
-
-
- HY-B2099S
-
|
Buformin-d9 (hydrochloride) is the deuterium labeled Buformin. Buformin (1-Butylbiguanide), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al)[1].
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: